Mitomycin-induced pulmonary veno-occlusive disease: Evidence from human disease and animal models

Circulation

Volumn 132, Issue 9, 2015, Pages 834-847

  Perros, Frédéric ^a,b,c   Günther, Sven ^a,b   Ranchoux, Benoit ^a,b   Godinas, Laurent ^a,b,d   Antigny, Fabrice ^a,b   Chaumais, Marie Camille ^a,e   Dorfmüller, Peter ^a,f   Hautefort, Aurélie ^a,b   Raymond, Nicolas ^a   Savale, Laurent ^a,b   Jaïs, Xavier ^a,b   Girerd, Barbara ^a,b   Cottin, Vincent ^g   Sitbon, Olivier ^a,b   Simonneau, Gerald ^a,b   Humbert, Marc ^a,b   Montani, David ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e HÔPITAL ANTOINE BÉCLÈRE   (France)

^f CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^g LOUIS PRADEL HOSPITAL   (France)

Author keywords

alkylating agents; antineoplastic agents; complications; drug related side effects and adverse reactions; GCN2; hypertension, pulmonary; pulmonary veno occlusive disease

Indexed keywords

AMIFOSTINE; BRAIN NATRIURETIC PEPTIDE; FLUOROURACIL; MITOMYCIN; NUCLEAR PROTEIN; PROTEIN GCN2; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANUS CANCER; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG INDUCED DISEASE; ECHOCARDIOGRAPH; FEMALE; FRENCHMAN; HEART CATHETERIZATION; HEART OUTPUT; HUMAN; HYPOXEMIA; IN VIVO STUDY; INCIDENCE; KINETICS; LIMIT OF QUANTITATION; LUNG HEMODYNAMICS; LUNG RESISTANCE; MALE; MIDDLE AGED; MITOMYCIN INDUCED PULMONARY VENO OCCLUSIVE DISEASE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; PROSPECTIVE STUDY; PROTEIN CONTENT; PROTEIN EXPRESSION; PULMONARY VENO-OCCLUSIVE DISEASE; RANDOMIZED CONTROLLED TRIAL; RAT; REGISTER; SEX DIFFERENCE; SQUAMOUS ANAL CANCER; TOXICOLOGY; TRANSDUCER; TRANSTHORACIC ECHOCARDIOGRAPHY; WESTERN BLOTTING; ANIMAL; ANUS NEOPLASMS; CHEMICALLY INDUCED; DISEASE MODEL; WISTAR RAT;

ADULT; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANUS NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; PROSPECTIVE STUDIES; PULMONARY VENO-OCCLUSIVE DISEASE; RATS; RATS, WISTAR; REGISTRIES;

EID: 84940417913     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.014207     Document Type: Article

References (38)

1. Montani D, Price LC, Dorfmuller P, Achouh L, Jaïs X, Yaïci A, Sitbon O, Musset D, Simonneau G, Humbert M, Pulmonary veno-occlusive disease. Eur Respir J 2009 33 189 200. doi: 10.1183/09031936.00090608
2. Mandel J, Mark EJ, Hales CA, Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000 162 1964 1973. doi: 10.1164/ajrccm.162.5.9912045
3. Wagenvoort CA, Wagenvoort N, Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970 42 1163 1184
4. Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, Chelghoum N, Coulet F, Bonnet D, Dorfmüller P, Fadel E, Sitbon O, Simonneau G, Tregouët DA, Humbert M, Soubrier F, EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014 46 65 69. doi: 10.1038/ng.2844
5. Joselson R, Warnock M, Pulmonary veno-occlusive disease after chemotherapy. Hum Pathol 1983 14 88 91
6. Ranchoux B, Günther S, Quarck R, Chaumais M-C, Dorfmüller P, Antigny F, Dumas SJ, Raymond N, Lau E, Savale L, Jais X, Simonneau G, Stenmark K, Cohen-Kaminsky S, Humbert M, Montani D, Perros F, Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol 2015 185 356 71
7. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaïci A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jaïs X, Montani D, Souza R, Simonneau G, Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010 122 156 163. doi: 10.1161/CIRCULATIONAHA.109.911818
8. Humbert M, Sitbon O, Yaïci A, Montani D, O'Callaghan DS, Jaïs X, Parent F, Savale L, Natali D, Günther S, Chaouat A, Chabot F, Cordier JF, Habib G, Gressin V, Jing ZC, Souza R, Simonneau G, French Pulmonary Arterial Hypertension Network Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010 36 549 555. doi: 10.1183/09031936.00057010
9. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G, Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006 173 1023 1030. doi: 10.1164/rccm.200510-1668OC
10. Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Hervé P, Simonneau G, Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005 111 3105 3111. doi: 10.1161/CIRCULATIONAHA.104.488486
11. Urboniene D, Haber I, Fang YH, Thenappan T, Archer SL, Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2010 299 L401 L412. doi: 10.1152/ajplung.00114.2010
12. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB, Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010 23 685 713; quiz 786. doi: 10.1016/j.echo.2010.05.010
13. Perros F, Dorfmüller P, Souza R, Durand-Gasselin I, Mussot S, Mazmanian M, Hervé P, Emilie D, Simonneau G, Humbert M, Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J 2007 29 462 468. doi: 10.1183/09031936.00094706
14. Chesné J, Danger R, Botturi K, Reynaud-Gaubert M, Mussot S, Stern M, Danner-Boucher I, Mornex JF, Pison C, Dromer C, Kessler R, Dahan M, Brugière O, Le Pavec J, Perros F, Humbert M, Gomez C, Brouard S, Magnan A, COLT Consortium Systematic analysis of blood cell transcriptome in end-stage chronic respiratory diseases. PLoS One 2014 9 e109291. doi: 10.1371/journal.pone.0109291
15. Abramowitz L, Rémy V, Vainchtock A, Economic burden of anal cancer management in France. Rev Epidemiol Sante Publique 2010 58 331 338. doi: 10.1016/j.respe.2010.06.165
16. Sztrymf B, Coulet F, Girerd B, Yaici A, Jais X, Sitbon O, Montani D, Souza R, Simonneau G, Soubrier F, Humbert M, Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008 177 1377 1383. doi: 10.1164/rccm.200712-1807OC
17. Knight BK, Rose AG, Pulmonary veno-occlusive disease after chemotherapy. Thorax 1985 40 874 875
18. Gagnadoux F, Capron F, Lebeau B, Pulmonary veno-occlusive disease after neoadjuvant mitomycin chemotherapy and surgery for lung carcinoma. Lung Cancer 2002 36 213 215
19. Swift GL, Gibbs A, Campbell IA, Wagenvoort CA, Tuthill D, Pulmonary veno-occlusive disease and Hodgkin's lymphoma. Eur Respir J 1993 6 596 598
20. Waldhorn RE, Tsou E, Smith FP, Kerwin DM, Pulmonary veno-occlusive disease associated with microangiopathic hemolytic anemia and chemotherapy of gastric adenocarcinoma. Med Pediatr Oncol 1984 12 394 396
21. Okuno SH, Frytak S, Mitomycin lung toxicity. Acute and chronic phases. Am J Clin Oncol 1997 20 282 284
22. Curado MP, International Agency for Research on Cancer, International Association of Cancer Registries Cancer incidence in five continents 2008 Volume IX Lyon; Geneva International Agency for Research on Cancer; Distributed by WHO Press, World Health Organization
23. Savale L, Chaumais MC, Cottin V, Bergot E, Frachon I, Prevot G, Pison C, Dromer C, Poubeau P, Lamblin N, Habib G, Reynaud-Gaubert M, Bourdin A, Sanchez O, Tubert-Bitter P, Jaïs X, Montani D, Sitbon O, Simonneau G, Humbert M, Pulmonary hypertension associated with benfluorex exposure. Eur Respir J 2012 40 1164 1172. doi: 10.1183/09031936.00188611
24. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, Bouvaist H, Canuet M, Pison C, Macro M, Poubeau P, Girerd B, Natali D, Guignabert C, Perros F, O'Callaghan DS, Jaïs X, Tubert-Bitter P, Zalcman G, Sitbon O, Simonneau G, Humbert M, Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012 125 2128 2137. doi: 10.1161/CIRCULATIONAHA.111.079921
25. Montani D, Achouh L, Dorfmüller P, Le Pavec J, Sztrymf B, Tchérakian C, Rabiller A, Haque R, Sitbon O, Jaïs X, Dartevelle P, Maître S, Capron F, Musset D, Simonneau G, Humbert M, Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008 87 220 233. doi: 10.1097/MD.0b013e31818193bb
26. Humbert M, Maître S, Capron F, Rain B, Musset D, Simonneau G, Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med 1998 157 5 pt 1 1681 1685. doi: 10.1164/ajrccm.157.5.9708065
27. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC), European Respiratory Society (ERS), International Society of Heart and Lung Transplantation (ISHLT) Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery J-L, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC), European Respiratory Society (ERS), International Society of Heart and Lung Transplantation (ISHLT) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009 34 1219 1263
28. Bradner WT, Mitomycin C: a clinical update. Cancer Treat Rev 2001 27 35 50. doi: 10.1053/ctrv.2000.0202
29. Hoorn CM, Wagner JG, Petry TW, Roth RA, Toxicity of mitomycin C toward cultured pulmonary artery endothelium. Toxicol Appl Pharmacol 1995 130 87 94. doi: 10.1006/taap.1995.1012
30. Verweij J, van Zanten T, Souren T, Golding R, Pinedo HM, Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis. Cancer 1987 60 756 761
31. Siegel D, Franklin WA, Ross D, Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res 1998 4 2065 2070
32. Gatzemeier U, Fasske E, Nowak U, Experimental and clinical data of the pulmonary toxicity of mitomycin C [in German]. Pneumologie 1990 44 suppl 1) 201 203
33. Schraufnagel DE, Sekosan M, McGee T, Thakkar MB, Human alveolar capillaries undergo angiogenesis in pulmonary veno-occlusive disease. Eur Respir J 1996 9 346 350
34. Ruiter G, de Man FS, Schalij I, Sairras S, Grünberg K, Westerhof N, van Der Laarse WJ, Vonk-Noordegraaf A, Reversibility of the monocrotaline pulmonary hypertension rat model. Eur Respir J 2013 42 553 556. doi: 10.1183/09031936.00012313
35. Duperray A, Tranqui L, Alix JL, Cordonnier D, Effect of mitomycin C on prostacyclin synthesis by human endothelial cells. Biochem Pharmacol 1988 37 4753 4757
36. Rockwell S, Cytotoxicities of mitomycin C and x rays to aerobic and hypoxic cells in vitro. Int J Radiat Oncol Biol Phys 1982 8 1035 1039
37. Wilson GJ, Bunpo P, Cundiff JK, Wek RC, Anthony TG, The eukaryotic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment. Am J Physiol Endocrinol Metab 2013 305 E1124 E1133. doi: 10.1152/ajpendo.00080.2013
38. Lathen C, Zhang Y, Chow J, Singh M, Lin G, Nigam V, Ashraf YA, Yuan JX, Robbins IM, Thistlethwaite PA, ERG-APLNR axis controls pulmonary venule endothelial proliferation in pulmonary veno-occlusive disease. Circulation 2014 130 1179 1191. doi: 10.1161/CIRCULATIONAHA.113.007822